In the UK, our team has switched from election elation to football fever with chants of ‘Football’s coming home’ while our Cricket Crazy colleagues in India have had a similar switch culminating in winning the T20 Mens Cricket World Cup.
All this sporting success hasn’t distracted the o2h Discovery team from expanding its collaborator base and building further capabilities in its Ahmedabad, India, and Cambridge, UK R&D sites. Our new R&D site in India is firmly up and running, and we have been welcoming visitors from across the globe. We have continued to build our chemistry and biology service offering with an expansion of our Fragment Library and PROTAC Toolbox as well as starting new projects formulating LNPs, non-GMP Scale-up, and synthesizing novel Peptides. Our core strength remains in supporting small molecule drug discovery projects with our engine of 500+ scientific professionals working on Hit ID through to Drug Candidates leveraging our strong medicinal chemistry base and our UK/India biology capabilities. o2h Discovery is celebrating its 20th year in operation since its first multi-FTE collaboration.
Best Wishes,
Team @ o2h discovery
|
|
|
Expanding Drug Discovery Innovation - Boston Office Launch
|
|
We were pleased to welcome Cat Stace to our Business Development team to continue to build on our partnerships in Boston. o2h discovery had recognised Boston as a key hub for Biotech as early as 2004 when we first started a collaboration there. The CIC offices in Boston provide a great place for us to meet collaborators and attend the buzzy CIC events which they have become known for.
|
|
|
|
Podium Partner of Biotech Bikers
|
|
We're proud to be one of the Podium Partners of Biotech Bikers, as we have cherished the Biotech Bikers experience for the past few years, enjoying Saturday rides through Cambridgeshire's picturesque countryside. Networking with like-minded biotech enthusiasts over lunch has been wonderful. We love combining biking with impactful biotech conversations and are excited to continue promoting entrepreneurship and innovation through this partnership. Read more
|
|
|
|
The o2h Fast Pharma 18 Campaign
|
|
We have recently initiated o2h Fast Pharma 18 to provide dedicated lab units with flexible contracts to venture-backed biotech and pharmaceutical companies to expedite their synthetic chemistry requirements for their fast-paced medicinal chemistry drug discovery programs. Read more
|
|
|
|
Service Capabilities - Chemistry
|
|
|
Solid-phase Peptide Synthesis
|
|
o2h Discovery has peptide synthesis, purification and characterisation capabilities. We synthesise peptides of 2-40 amino acids using the latest Fmoc solid-phase technology from mg to gram scale, and purify our products using HPLC. o2h discovery recently purchased a Biotage SYRO I, fully automated multi-channel peptide synthesiser.
To know more about our peptide synthesis service offering, please reach out to Claudio at discovery@o2h.com
|
|
|
o2h Business Development Team
|
|
|
We have now expanded our business development team…
|
|
Claudio Dagostin, VP Business Development, UK and EU
Claudio obtained his PhD in organic chemistry from the University of Rome and completed a postdoc at Imperial College London, focusing on Alzheimer’s disease chemical probes. He then worked in the Cambridge biotech cluster, as medicinal chemist specialising in Fragment-Based Drug Design for 13 years. Since 2017 he has worked in BD for several companies. He joined o2h in January 2021, where he oversees our BD strategy in the UK and EU.
|
|
|
Tejas Upadhyay, VP - Business Development (West Coast USA)
Tejas holds a PhD (chemistry) from India, with post-doctoral experience from the University of Glasgow. His career began at Alembic, followed by roles at Evotec, o2h, and Piramal. With over two decades in preclinical drug discovery, he now oversees all o2h projects in the West Coast region.
|
|
|
|
Catherine Stace, VP - Business Development (East Coast USA)
Catherine holds a PhD in Cell Biology from the University of Cambridge and an MBA from the Open University. Cat has over 18 years of experience in therapeutic discovery, with strategic roles in biotechnology, consultancy, and CRO organizations. She has contributed to small molecule therapeutics, peptides, health tech, and engineering. Before joining o2h, she was EVP of Business Development at Domainex, collaborating with companies in the UK, USA, and Europe. Cat now oversees o2h's business development on the East Coast USA.
|
|
|
Hemal Soni, VP (Chemistry) Australia and ROW
Hemal obtained a PhD in organic chemistry and has over 17 years of industrial experience in synthetic chemistry research and development. At o2h discovery, he oversees ongoing projects and helps initiate new programs. Hemal has worked with clients worldwide, including in the UK, USA, Japan, Australia, and Singapore. He also manages o2h's business in Australia and the rest of the world (ROW).
|
|
|
|
o2h discovery out & about
|
|
|
Claudio represented o2h discovery at #RESI Europe 2024 in Spain and the #BioTrinity conference in London. It provided an excellent opportunity to network, exchange ideas, and explore collaboration possibilities with early-stage startups.
|
|
|
|
J.P. Morgan Healthcare Conference
|
|
|
We had an enriching experience at the 42nd Annual J.P. Morgan Healthcare Conference. It was inspiring to connect with brilliant minds from groundbreaking biotech startups, meet talented medicinal chemists and scientists, and explore the latest advancements in global drug discovery.
|
|
|
|
Claudio and Keith attended the On Helix 2024 happened on 4 July 2024 at Cambridge, UK. The one-day conference addressed key bio innovation trends, from developments in life science and technology research to their translation into new diagnostics, prevention tools or treatments.
|
|
|
|
The 19th Annual Drug Discovery Chemistry Conference
|
|
|
Tejas represented o2h discovery at the 19th Annual Drug Discovery Chemistry Conference in San Diego, USA which was focused on the discovery and optimization challenges of small molecule drug candidates for tomorrow’s therapeutics.
|
|
|
|
Cat and Prashant attended the 10th LSX World Congress, which gathers founders and CEOs from innovative start-ups to healthcare giants and everyone in between. The event represented the breadth and depth of cutting-edge research and technology driving industry advancements now and in the near future.
|
|
|
XXVIII EFMC International Symposium on Medicinal Chemistry,
and NLS Days (Nordic Life Science Days) 2024
|
|
Claudio will be participating in two major events this year: first, the XXVIII EFMC International Symposium on Medicinal Chemistry in Italy from September 1-5, 2024, followed by NLS Days in Sweden from September 18-19, 2024. We look forward to meeting you there. If you would like to schedule a meeting, please reach out to us at discovery@o2h.com.
|
|
|
Discovery on Target (DOT)
|
|
|
Cat will be attending one of the Industry’s Preeminent Events on Novel Drug Targets and Technologies i.e., Discovery on Target, from Sept 30 - Oct 3, 2024, in Boston.
|
|
|
Cambridge Wide Open Day - Season 2
|
|
|
After the successful completion of the inaugural season of CWOD last year, we had an excellent kick-off to Cambridge Wide Open Day season 2 this year, featuring exceptional sessions, tours, and presentations that gave visitors valuable insights into Cambridge.
Read more - https://cambridgewideopenday.com/
|
|
|
|
We express our heartfelt gratitude for your continued support. The journey ahead promises even greater growth and impactful collaborations. Together, we will continue to contribute in innovation and achieve new milestones.
|
|
|
In case of any queries, please write us at discovery@o2h.com
|
|
|
|
